ReviewIn vivo (Athens, Greece)
Malignant Priapism - What Do We Know About It?
Review in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 13 citations in OpenAlex.
- A Case of Malignant Priapism Secondary to Muscle Invasive Bladder Cancer and Review of Palliative Management.Case reports in urology · 2025Article
- Penile Metastasis-Induced Priapism as the First Sign of Lung Cancer: A Case Report and Review of the Literature.Case reports in urology · 2024Article
- The Current Challenges in Diagnosing and Treating Malignant Priapism: A Comprehensive Review.Urology research & practice · 2023Article
- Malignant priapism: case report and update on management protocols.Translational andrology and urology · 2023Article
- Malignant priapism secondary from metastatic renal carcinoma: Case report: "Malignant Priapism from Kidney Neoplasm".Urology case reports · 2023Article
- Priapism in a Patient with Rectal Adenocarcinoma.Diseases (Basel, Switzerland) · 2023Article
- Review
- Updates in the use of radiotherapy in the management of primary and locally-advanced penile cancer.Asian journal of urology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignancy as an etiological factor involved in priapism pathogenesis is rare. Malignant priapism (MP) can arise as a result of penile tumor invasion, either from primary penile tumors or from metastatic penile tumors, or due to hematological malignancies. Non-urological penile metastases are associated with significant worse prognosis compared to urological penile metastases, the appearance of priapism in such cases affecting even more the prognosis and the survival of these patients. Patients diagnosed with hematological malignancies and priapism present significant higher survival rates compared to those who develop MP in the context of a non-hematological malignancy, this being related to the fact that hematological malignancies are more sensitive to chemo- and radiotherapy. Most malignant priapism cases are ischemic; therefore the management should be based on the initial steps of the IP therapeutic protocol. Considering the trigger factor that has led to the priapic event specific oncologic treatment can be added as well.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.